SGX Stocks :: Your One Stop SGX Stocks Info Blog

• Revenue: -5% (2Q09), -3% (1H09)
• Net Profit: -15% (2Q09), -15% (1H09)
• Press Release: Strong demand for LMA Supreme
• Increased focus on R&D
• Improved Urology business
• Outlook: LMA anticipates that the general financial and economic environments, which have impacted its performance to date, will continue to impact the medical device market through 2009 and potentially beyond.
• Reported results from various healthcare and medical device companies have indicated that these factors have adversely impacted their performance.
• The LMA SupremeTM continues to be well received by clinicians and future sales are expected to increase significantly.
• Steps have been taken to increase manufacturing capacity accordingly over the next 18 months.
• Additionally, LMA has also decided to invest in its own manufacturing facility for certain key products.
• This decision will enable LMA to have dual source of supply, have lower cost of goods and reduce dependence on external contract manufacturers.
• As indicated above, increased R&D investment is being made to reduce manufacturing costs of its LMA PerfecTemp device, the results of which are expected to be realised at the end of the current year.
• The Cook distribution arrangement is expected to significantly improve the performance of the Urology division.

FINANCIAL RECORDS

Revenue (USD '000)

FY 1Q 2Q 3Q 4Q Total
2009 24,235 27,371
2008 24,469 28,585 28,041 27,355 108,450
2007 23,570 27,846 22,863 25,337 99,616
2006 20,451 24,368 22,096 23,674 90,589
2005 20,577 21,501 20,963 23,273 86,314
2004 17,939 19,080 19,029 22,110 78,158
-----------------------------------------------------------
Earnings (USD '000)

FY 1Q 2Q 3Q 4Q Total
2009 1,498 3,637
2008 2,554 4,272 2,875 (855) 8,846
2007 3,489 5,489 1,230 2,508 12,716
2006 4,336 7,472 5,255 5,474 22,537
2005 (21,136) 6,297 5,886 6,415 (2,538)
2004 5,786 5,612 5,126 5,889 22,413
-----------------------------------------------------------
Dividends

FY Interim Final Special (SGD)
NA
-----------------------------------------------------------
Bonus / Rights / Stock Split

Date Type Details
NA
-----------------------------------------------------------
Share Data (USD)

NAV = $0.18131
EPS = $0.00965 (6M FY09)
No of Shares = 544,584,941
-----------------------------------------------------------

ANALYSTS' TARGET PRICES

Broker Recommendation Target Price Date
NA